Tagged with R

Taiwan The TGPA’s Tiffany Chen brings over three decades of experience at the intersection of pharmaceuticals, public policy, and industry development. In her current role, she leads advocacy efforts to strengthen regulatory and reimbursement frameworks, safeguard sustainable margins, and reinforce supply resilience in Taiwan. At the same time, she also works…

USA Matt Heck, founder and CEO of Sentynl Therapeutics, outlines the company’s acquisition-led rare disease strategy following its integration into Zydus Group in 2017. He discusses building a focused portfolio of life-extending paediatric therapies, leveraging orphan drug incentives, prioritising early diagnosis, expanding internationally, and partnering closely with patient foundations to maximise…

Hong Kong Roche Diagnostics Hong Kong is entering a defining phase as the city accelerates its shift toward primary care, early detection and data-driven decision making. In this interview, General Manager Ronald Lo reflects on eighteen months of strategic progress, from expanding point-of-care testing and preparing breakthrough Alzheimer’s‑related biomarkers to shaping regulatory…

Europe Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share of a global market set to top USD 93.7 billion by 2030   The field can already boast two bona-fide…

Taiwan Dr David Chang discusses his vision for establishing the world’s premier cell and gene therapy contract development and manufacturing organisation in Taiwan. Drawing on more than 30 years of experience at Celgene, Roche, and Genentech, Dr Chang explains how Taiwan’s unique combination of technical talent, cost efficiency, and geopolitical positioning…

UAE In less than a decade, the Abu Dhabi Stem Cells Center has emerged as a central pillar in the UAE’s ambition to build a fully integrated ecosystem for advanced therapies. From pandemic-era clinical trials to the establishment of the country’s first bone marrow transplant and locally manufactured CAR-T programmes, ADSCC…

USA Jeff Allen is the President & CEO of Friends of Cancer Research, a research policy and advocacy organisation based in Washington, DC. His organisation works to accelerate the development of cancer therapies through evidence-based policy and collaborative research partnerships. Allen highlights the importance of diagnostics and biomarker testing to help…

France In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state subsidies in rival markets.   “France’s industrial fabric risks being systematically hollowed out if we don’t act fast to mitigate…

France France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are the threats to further collaborations in the coming years?   For a country with a population of just six million…

France France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as a benchmark internationally, and which few other countries have proven able to match.   “Back in the mid-2000s, under the…

France France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis Pasteur’s work on germ theory and pasteurisation in the 19th century laid the groundwork for much of what we know…

France France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left by private industry and the state while elevating the concerns of the most important people within healthcare: patients and their…